155 related articles for article (PubMed ID: 35269787)
21. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
Liu D; Liu X; Xing M
Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
[TBL] [Abstract][Full Text] [Related]
23. Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness.
Meng P; Bedolla RG; Yun H; Fitzpatrick JE; Kumar AP; Ghosh R
Mol Carcinog; 2019 Sep; 58(9):1701-1710. PubMed ID: 31124185
[TBL] [Abstract][Full Text] [Related]
24. Histologic and Phenotypic Factors and MC1R Status Associated with BRAF(V600E), BRAF(V600K), and NRAS Mutations in a Community-Based Sample of 414 Cutaneous Melanomas.
Hacker E; Olsen CM; Kvaskoff M; Pandeya N; Yeo A; Green AC; Williamson RM; Triscott J; Wood D; Mortimore R; Hayward NK; Whiteman DC
J Invest Dermatol; 2016 Apr; 136(4):829-837. PubMed ID: 26807515
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
26. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
27. [Biological role and prognostic significance of genetic alterations in human malignant melanomas].
Vízkeleti L
Magy Onkol; 2015 Sep; 59(3):268-72. PubMed ID: 26339916
[TBL] [Abstract][Full Text] [Related]
28. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
Goto K; Yoshikawa S; Kiyohara Y; Kukita Y; Miura K; Oishi T
J Cutan Pathol; 2022 Apr; 49(4):393-398. PubMed ID: 34792818
[TBL] [Abstract][Full Text] [Related]
29. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
30. Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry.
Urvanegia AC; Tavoloni Braga JC; Shitara D; Fregnani JH; Neves JI; Pinto CA; Marghoob AA; Duprat JP; Rezze GG
PLoS One; 2017; 12(6):e0179745. PubMed ID: 28662062
[TBL] [Abstract][Full Text] [Related]
31. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
Mitchell B; Leone D; Feller JK; Bondzie P; Yang S; Park HY; Mahalingam M
Melanoma Res; 2014 Dec; 24(6):621-5. PubMed ID: 25211166
[TBL] [Abstract][Full Text] [Related]
32. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo.
Jalili A; Mertz KD; Romanov J; Wagner C; Kalthoff F; Stuetz A; Pathria G; Gschaider M; Stingl G; Wagner SN
PLoS One; 2013; 8(7):e69064. PubMed ID: 23935925
[TBL] [Abstract][Full Text] [Related]
33. Functional RET G691S polymorphism in cutaneous malignant melanoma.
Narita N; Tanemura A; Murali R; Scolyer RA; Huang S; Arigami T; Yanagita S; Chong KK; Thompson JF; Morton DL; Hoon DS
Oncogene; 2009 Aug; 28(34):3058-68. PubMed ID: 19561646
[TBL] [Abstract][Full Text] [Related]
34. Inducible BRAF suppression models for melanoma tumorigenesis.
Hoeflich KP; Jaiswal B; Davis DP; Seshagiri S
Methods Enzymol; 2008; 439():25-38. PubMed ID: 18374154
[TBL] [Abstract][Full Text] [Related]
35. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.
Kannengiesser C; Spatz A; Michiels S; Eychène A; Dessen P; Lazar V; Winnepenninckx V; Lesueur F; Druillennec S; Robert C; van den Oord JJ; Sarasin A; Bressac-de Paillerets B;
Mol Oncol; 2008 Apr; 1(4):425-30. PubMed ID: 19383316
[TBL] [Abstract][Full Text] [Related]
36. BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression.
Ehsani L; Cohen C; Fisher KE; Siddiqui MT
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):648-51. PubMed ID: 25046227
[TBL] [Abstract][Full Text] [Related]
37. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.
Yu H; McDaid R; Lee J; Possik P; Li L; Kumar SM; Elder DE; Van Belle P; Gimotty P; Guerra M; Hammond R; Nathanson KL; Dalla Palma M; Herlyn M; Xu X
Am J Pathol; 2009 Jun; 174(6):2367-77. PubMed ID: 19389934
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma.
Capparelli C; Rosenbaum S; Berger AC; Aplin AE
J Biol Chem; 2015 Oct; 290(40):24267-77. PubMed ID: 26269601
[TBL] [Abstract][Full Text] [Related]
39. Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated.
Al Hashmi M; Sastry KS; Silcock L; Chouchane L; Mattei V; James N; Mathew R; Bedognetti D; De Giorgi V; Murtas D; Liu W; Chouchane A; Temanni R; Seliger B; Wang E; Marincola FM; Tomei S
J Transl Med; 2020 May; 18(1):192. PubMed ID: 32393282
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
